330 related articles for article (PubMed ID: 28240663)
41. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
42. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors.
Haug AR; Cindea-Drimus R; Auernhammer CJ; Reincke M; Wängler B; Uebleis C; Schmidt GP; Göke B; Bartenstein P; Hacker M
J Nucl Med; 2012 Nov; 53(11):1686-92. PubMed ID: 22984220
[TBL] [Abstract][Full Text] [Related]
43. ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.
Subramaniam RM; Bradshaw ML; Lewis K; Pinho D; Shah C; Walker RC
Clin Nucl Med; 2018 Dec; 43(12):899-908. PubMed ID: 30394933
[TBL] [Abstract][Full Text] [Related]
44. Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.
Al-Toubah T; Montilla-Soler J; El-Haddad G; Haider M; Strosberg J
J Nucl Med; 2023 Dec; 64(12):1895-1898. PubMed ID: 37797976
[TBL] [Abstract][Full Text] [Related]
45. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
Lastoria S; Marciello F; Faggiano A; Aloj L; Caracò C; Aurilio M; D'Ambrosio L; Di Gennaro F; Ramundo V; Camera L; De Luca L; Fonti R; Napolitano V; Colao A
Endocrine; 2016 Jun; 52(3):488-94. PubMed ID: 26242621
[TBL] [Abstract][Full Text] [Related]
46. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.
Hindié E
Theranostics; 2017; 7(5):1159-1163. PubMed ID: 28435455
[TBL] [Abstract][Full Text] [Related]
47. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients.
Fendler WP; Barrio M; Spick C; Allen-Auerbach M; Ambrosini V; Benz M; Bluemel C; Grewal RK; Lapa C; Miederer M; Nicolas G; Schuster T; Czernin J; Herrmann K
J Nucl Med; 2017 Feb; 58(2):307-311. PubMed ID: 27539839
[TBL] [Abstract][Full Text] [Related]
48. The utility of
Tirosh A; Kebebew E
Future Oncol; 2018 Jan; 14(2):111-122. PubMed ID: 29072093
[TBL] [Abstract][Full Text] [Related]
49. 68Ga-DOTATATE PET/MRI for Neuroendocrine Tumors: A Pictorial Review.
Nguyen NC; Moon CH; Muthukrishnan A; Furlan A
Clin Nucl Med; 2020 Sep; 45(9):e406-e410. PubMed ID: 32520493
[TBL] [Abstract][Full Text] [Related]
50. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.
Hofman MS; Kong G; Neels OC; Eu P; Hong E; Hicks RJ
J Med Imaging Radiat Oncol; 2012 Feb; 56(1):40-7. PubMed ID: 22339744
[TBL] [Abstract][Full Text] [Related]
51. Increased Activity Due to Fractures Does Not Significantly Affect the Accuracy of 68Ga-DOTATATE PET/CT in the Detection of Culprit Tumor in the Evaluation of Tumor-Induced Osteomalacia.
Ding J; Hu G; Wang L; Li F; Huo L
Clin Nucl Med; 2018 Dec; 43(12):880-886. PubMed ID: 30273206
[TBL] [Abstract][Full Text] [Related]
52. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.
Herrmann K; Czernin J; Wolin EM; Gupta P; Barrio M; Gutierrez A; Schiepers C; Mosessian S; Phelps ME; Allen-Auerbach MS
J Nucl Med; 2015 Jan; 56(1):70-5. PubMed ID: 25500825
[TBL] [Abstract][Full Text] [Related]
53. Parametric Net Influx Rate Images of
Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
[No Abstract] [Full Text] [Related]
54. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.
Johnbeck CB; Knigge U; Kjær A
Future Oncol; 2014 Nov; 10(14):2259-77. PubMed ID: 25471038
[TBL] [Abstract][Full Text] [Related]
55. Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors.
You H; Kandathil A; Beg M; De Blanche L; Kazmi S; Subramaniam RM
Nucl Med Commun; 2020 Oct; 41(10):1060-1065. PubMed ID: 32732600
[TBL] [Abstract][Full Text] [Related]
56. Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT.
Van Binnebeek S; Koole M; Terwinghe C; Baete K; Vanbilloen B; Haustermans K; Clement PM; Bogaerts K; Verbruggen A; Nackaerts K; Van Cutsem E; Verslype C; Mottaghy FM; Deroose CM
Nuklearmedizin; 2016 Jun; 55(3):104-14. PubMed ID: 27056060
[TBL] [Abstract][Full Text] [Related]
57. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A
J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
[TBL] [Abstract][Full Text] [Related]
58. 68Ga-DOTATATE: Significance of Uptake in the Tail of the Pancreas in Patients Without Lesions.
Delbeke D; Newman G; Deppen S; Shah C; Ndolo J; Shi C; Bailey CE; Jessop AC; Sandler MP
Clin Nucl Med; 2019 Nov; 44(11):851-854. PubMed ID: 31524686
[TBL] [Abstract][Full Text] [Related]
59. A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET/CT uptake by primary site-dependent neuroendocrine tumor metastasis.
Kunikowska J; Pawlak D; Kolasa A; Mikołajczak R; Królicki L
Clin Nucl Med; 2014 Oct; 39(10):855-61. PubMed ID: 25072928
[TBL] [Abstract][Full Text] [Related]
60. Brain Metastases of a Neuroendocrine Tumor Visualized by 68Ga-DOTATATE PET/CT.
Hoberück S; Michler E; Zöphel K; Platzek I; Kotzerke J; Brogsitter C
Clin Nucl Med; 2019 Jan; 44(1):50-52. PubMed ID: 30371585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
